Identification of new biomarkers of bronchopulmonary dysplasia using metabolomics

Fiammetta Piersigilli, TuKiet T Lam, Pamela Vernocchi, Andrea Quagliariello, Lorenza Putignani, Zubair H Aghai, Vineet Bhandari

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: To identify new biomarkers of bronchopulmonary dysplasia (BPD) in preterm neonates.

STUDY DESIGN: Metabolomic study of prospectively collected tracheal aspirate (TA) samples from preterm neonates admitted in 2 neonatal intensive care units measured by a mass spectroscopy-based assay and analysed using partial least squares-discriminant analysis.

RESULTS: We evaluated 160 TA samples from 68 neonates, 44 with BPD and 24 without BPD in the first week of life. A cluster of 53 metabolites was identified as characteristic of BPD, with 18 select metabolites being highly significant in the separation of BPD versus No BPD. To control for the gestational age (GA) differences, we did a sub-group analyses, and noted that the amino acids histidine, glutamic acid, citrulline, glycine and isoleucine levels were higher in neonates with BPD. In addition, acylcarnitines C16-OH and C18:1-OH were also higher in neonates who developed BPD, but especially in the most preterm infants (neonates with GA < 27 weeks).

CONCLUSION: Metabolomics is a promising approach to identify novel specific biomarkers for BPD.

Original languageEnglish
Pages (from-to)20
JournalMetabolomics
Volume15
Issue number2
DOIs
Publication statusPublished - Feb 2 2019

Fingerprint

Bronchopulmonary Dysplasia
Metabolomics
Biomarkers
Metabolites
Intensive care units
Citrulline
Isoleucine
Discriminant analysis
Histidine
Newborn Infant
Glycine
Glutamic Acid
Assays
Spectroscopy
Amino Acids
Gestational Age
Neonatal Intensive Care Units
Discriminant Analysis
Least-Squares Analysis
Premature Infants

Cite this

Identification of new biomarkers of bronchopulmonary dysplasia using metabolomics. / Piersigilli, Fiammetta; Lam, TuKiet T; Vernocchi, Pamela; Quagliariello, Andrea; Putignani, Lorenza; Aghai, Zubair H; Bhandari, Vineet.

In: Metabolomics, Vol. 15, No. 2, 02.02.2019, p. 20.

Research output: Contribution to journalArticle

@article{3d18b52fb2e74ff183647ee01e084b7f,
title = "Identification of new biomarkers of bronchopulmonary dysplasia using metabolomics",
abstract = "OBJECTIVE: To identify new biomarkers of bronchopulmonary dysplasia (BPD) in preterm neonates.STUDY DESIGN: Metabolomic study of prospectively collected tracheal aspirate (TA) samples from preterm neonates admitted in 2 neonatal intensive care units measured by a mass spectroscopy-based assay and analysed using partial least squares-discriminant analysis.RESULTS: We evaluated 160 TA samples from 68 neonates, 44 with BPD and 24 without BPD in the first week of life. A cluster of 53 metabolites was identified as characteristic of BPD, with 18 select metabolites being highly significant in the separation of BPD versus No BPD. To control for the gestational age (GA) differences, we did a sub-group analyses, and noted that the amino acids histidine, glutamic acid, citrulline, glycine and isoleucine levels were higher in neonates with BPD. In addition, acylcarnitines C16-OH and C18:1-OH were also higher in neonates who developed BPD, but especially in the most preterm infants (neonates with GA < 27 weeks).CONCLUSION: Metabolomics is a promising approach to identify novel specific biomarkers for BPD.",
author = "Fiammetta Piersigilli and Lam, {TuKiet T} and Pamela Vernocchi and Andrea Quagliariello and Lorenza Putignani and Aghai, {Zubair H} and Vineet Bhandari",
year = "2019",
month = "2",
day = "2",
doi = "10.1007/s11306-019-1482-9",
language = "English",
volume = "15",
pages = "20",
journal = "Metabolomics",
issn = "1573-3882",
publisher = "Springer New York",
number = "2",

}

TY - JOUR

T1 - Identification of new biomarkers of bronchopulmonary dysplasia using metabolomics

AU - Piersigilli, Fiammetta

AU - Lam, TuKiet T

AU - Vernocchi, Pamela

AU - Quagliariello, Andrea

AU - Putignani, Lorenza

AU - Aghai, Zubair H

AU - Bhandari, Vineet

PY - 2019/2/2

Y1 - 2019/2/2

N2 - OBJECTIVE: To identify new biomarkers of bronchopulmonary dysplasia (BPD) in preterm neonates.STUDY DESIGN: Metabolomic study of prospectively collected tracheal aspirate (TA) samples from preterm neonates admitted in 2 neonatal intensive care units measured by a mass spectroscopy-based assay and analysed using partial least squares-discriminant analysis.RESULTS: We evaluated 160 TA samples from 68 neonates, 44 with BPD and 24 without BPD in the first week of life. A cluster of 53 metabolites was identified as characteristic of BPD, with 18 select metabolites being highly significant in the separation of BPD versus No BPD. To control for the gestational age (GA) differences, we did a sub-group analyses, and noted that the amino acids histidine, glutamic acid, citrulline, glycine and isoleucine levels were higher in neonates with BPD. In addition, acylcarnitines C16-OH and C18:1-OH were also higher in neonates who developed BPD, but especially in the most preterm infants (neonates with GA < 27 weeks).CONCLUSION: Metabolomics is a promising approach to identify novel specific biomarkers for BPD.

AB - OBJECTIVE: To identify new biomarkers of bronchopulmonary dysplasia (BPD) in preterm neonates.STUDY DESIGN: Metabolomic study of prospectively collected tracheal aspirate (TA) samples from preterm neonates admitted in 2 neonatal intensive care units measured by a mass spectroscopy-based assay and analysed using partial least squares-discriminant analysis.RESULTS: We evaluated 160 TA samples from 68 neonates, 44 with BPD and 24 without BPD in the first week of life. A cluster of 53 metabolites was identified as characteristic of BPD, with 18 select metabolites being highly significant in the separation of BPD versus No BPD. To control for the gestational age (GA) differences, we did a sub-group analyses, and noted that the amino acids histidine, glutamic acid, citrulline, glycine and isoleucine levels were higher in neonates with BPD. In addition, acylcarnitines C16-OH and C18:1-OH were also higher in neonates who developed BPD, but especially in the most preterm infants (neonates with GA < 27 weeks).CONCLUSION: Metabolomics is a promising approach to identify novel specific biomarkers for BPD.

U2 - 10.1007/s11306-019-1482-9

DO - 10.1007/s11306-019-1482-9

M3 - Article

C2 - 30830433

VL - 15

SP - 20

JO - Metabolomics

JF - Metabolomics

SN - 1573-3882

IS - 2

ER -